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Summary
Objectives: To evaluate the survival of patients with heart failure submitted to cardiac transplantation screening as well 
as identify poor prognostic factors using a risk score to identify patients with higher death risk.
Methods: 330 male and female patients aged 12 to 74 years old, referred for heart transplantation from January 1986 to 
November 2001 were evaluated. Clinical, laboratory, electrocardiographic, Holter monitoring, echocardiographic and 
radionuclide ventriculography data were analyzed.
Results: The median follow up period was 5 years; patients’ survival rate was 84.5% in the first year, 74.3% in the second 
year, 68.9% in the third year and 60.5% in the fifth year. The prognostic variables selected through the univariate analysis 
were: age, Chagas’ disease etiology for cardiomyopathy, NYHA functional classes III and IV, orthopnea, systolic blood 
pressure, mean blood pressure, pulse pressure, plasma urea, sodium, glucose, albumin, bilirubin, hemoglobin, and mean 
heart rate. The prognostic variables at the multivariate analysis were: ejection fraction, blood urea, and hemoglobin. 
The risk score: RR=exp[(-0.0942401 x ejection fraction) + (0.0105207 x blood urea) + (-0.2974991 x hemoglobin) + (-
0.0132898 x age) + (-0.0099115 x blood glucose)] discriminated the population with a higher death risk.
Conclusion: Patients’ survival was satisfactory despite heart failure severity, suggesting they can be maintained on 
optimized clinical treatment until persistent clinical deterioration takes place. Ejection fraction, ventricular diameters, 
and clinical functional class alone should not be used as an indication for heart transplantation. The risk score could 
help discriminate the population with the poorest prognosis. (Arq Bras Cardiol 2007;88(6):590-595)
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Introduction
Approximately 5,000,000 North-Americans present 
heart failure (HF), with an incidence of 10/1,000 among 
individuals older than 65 years. HF is the cause of around 
20% of all hospital admissions among individuals older 
than 65 years1. In Brazil, the importance of HF is similarly 
significant and according to data from the Ministry of Health 
(DATASUS/2000), there are currently 2,000,000 patients 
with HF and 240,000 new cases are diagnosed yearly2. 
Despite the therapeutic advances that have taken place in 
the last decades, HF is a disease with a severe prognosis, 
showing an annual mortality of 30 to 50% for the most 
critical patients3. Heart transplantation is currently the 
only broadly accepted surgical alternative to treat these 
patients with severe HF; however, there are limitations 
created by the higher number of receptors compared to the 
permanent scarcity of donors. The transplantation priority 
for hospitalized patients in critical condition is accepted 
worldwide; as for the outpatients, the conditions that are 
associated with HF mortality (prognostic factors) have been 
used as determinant factors for the heart transplantation 
indication and waiting list position in Brazil and other 
countries, as a priority criterion in this group of patients. 
The aim of the present study was to find the prognostic 
factors of HF in our country that would take clinical parameters 
into account and could contribute to the identification of 
patients with a higher death risk among those referred for 
heart transplantation and attempt to establish a risk score 
considering these factors.  
Methods
The study group consisted of 330 patients referred for heart 
transplantation assessment, from January 1986 to November 
2001, in a Reference Center for Heart Transplantation. 
Mean age was 43 ± 12 years (ranging from 12 to 74 yrs); 
77.3% of the patients were males with chronic HF: 124 had 
idiopathic dilated cardiomyopathy (IDCM), 94 had Chagasic 
cardiomyopathy (CCM), 64 had ischemic cardiopathy (IC) and 
48 had other etiologies. Patients were selected according to the 
inclusion criteria: 12 to 75 years of age, left ventricular ejection 
fraction < 40% at the two-dimensional echocardiography, 
symptomatic HF, New York Heart Association (NYHA) 
functional class II, III or IV, undergoing conventional drug 
therapy and being referred for heart transplantation. Patients 
were excluded when they presented severe concomitant 
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diseases that could affect the prognosis (chronic obstructive 
pulmonary disease, hepatic failure, insulin-dependent 
diabetes mellitus, stroke with severe sequelae and dementia, 
positive serology for HIV and chronic renal failure under 
dialysis treatment). The study protocol was approved by the 
Committee of Ethics on Research of our Institution. 
The beginning of the study enrolment coincided with the 
first outpatient visit with data collection on clinical history, 
usual medications, symptoms and physical examination; other 
variables were NYHA functional class, hospital admissions due 
to HF, use of vasoactive drugs, routine laboratory assessment, 
electrocardiogram (ECG), two-dimensional transthoracic 
echocardiogram with Doppler, radionuclide ventriculography 
and Holter monitoring. The functional analysis with a direct 
measurement of oxygen consumption (VO
2
) was carried 
out in a small number of patients and therefore, it was not 
included among the studied variables. Hemodynamic variables 
obtained through right and left heart catheterization, although 
available for most of the patients, were not considered for the 
assessment in the present study, due to its low level of feasibility 
at obtaining it by the clinicians who treat patients with HF.
For the statistical analysis, the event of interest was death 
due to cardiovascular disease; heart transplantation and other 
causes of death were suppressed. The descriptive analysis is 
demonstrated by mean ± SD and median and the survival 
curve by the actuarial method4 for the analysis of long-term 
survival. 
The prognostic assessment was carried out using the survival 
curve by the Kaplan-Meier method and the curves were 
compared using the log-rank test4 to identify a combination 
of significant prognostic factors. To determine independent 
survival predictors, Cox proportional hazards regression 
model5 was used. The significant predictors of the univariate 
analysis of the Cox proportional hazards regression model 
(p< 0.10) and other variables that were considered significant 
in other studies were analyzed at the multivariate model6. 
To explore the association between the selected variables, 
Spearman’s correlation coefficients and phi7 were calculated. 
The prognostic score was calculated for each patient 
(excluding the patients who underwent heart transplantation) 
as an exponential value of the sum product of the prognostic 
variables and their coefficient (RR=exp (β
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 are the values of the variables and 
β
1
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,... βn are the coefficients assigned to each variable. To 
establish a cutoff for this prognostic score, the ROC (Receiving 
Operating Characteristic) curve was used in order to show the 
clinical implications of accepting the different cutoff levels of 
the calculated prognostic score8.
The statistical analysis was carried out using the STATA 
7.0 software. 
Results
The final study group consisted of 330 patients (77.3% 
males, mean age 43 ± 12 yrs). Eighty-five (20.4%) of the 415 
patients that were initially selected were excluded as they did 
not meet the inclusion criteria.
The patients’ follow-up period had a median of 1,780 
days (ranging from 7 to 5,574); 99 patients (30%) died 
and 123 (37.3%) underwent heart transplantation due to 
terminal HF.
All of the patients were submitted to the conventional 
therapy, advised to maintain a low-sodium diet, hydric 
restriction and pharmacological treatment, which included 
angiotensin-converting enzyme inhibitors (ACEI), digitalis, 
diuretics, and in some patients, betablockers, amiodarone 
and oral anticoagulants. 
Long-term survival (actuarial method) was 84.5%, in the 1st 
year, 74.3% in the 2nd year, 68.9% in the 3rd year and 60.5% 
in the 5th year (Graphic 1).
Graphic 1 - 5-year actuarial survival curve for the 330 patients in the sample.
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At the assessment of the prognostic factors, the univariate 
analysis selected 15 variables (Table 1) as potential prognostic 
predictors (age, Chagasic etiology, functional class III or IV, 
orthopnea, systolic arterial pressure, mean arterial pressure, 
pulse pressure, plasma urea, plasma sodium, glycemia, 
albuminemia, serum total bilirubin, hemoglobin and mean HR 
at Holter monitoring). At the multivariate analysis (Table 2), 
the left ventricular ejection fraction (LVEF) by the radionuclide 
method (Hazard ratio [Hr] 0.091, p=0.004), plasma urea 
(Hr 1.01, p=0.007) and hemoglobin (Hr 0.742, p=0.003), 
were independent predictors of mortality. The left ventricular 
ejection fraction by the radionuclide method decreased the 
death risk by 9% for each 1% increase in its value. Plasma urea 
increased the death risk by 1% for each 1mg/dl increase in 
plasma levels.  Hemoglobin decreased the death risk by 74% 
as the hemoglobin levels increased 1g%. To adjust the statistical 
model and improve the information obtained from the set of 
data, age and plasma glycemia, which were not significant at 
the multivariate analysis, were maintained. 
The prognostic score was calculated for each patient 
individually, with individual risk factors being identified at 
the multivariate analysis (excluding the patients that were 
submitted to heart transplantation). The individual relative 
Table 2 - Cox proportional hazards regression model of the prognostic variables
Variable Coefficient Hazard ratio Standard error z p>| z |  95% CI
EF (RI) -0.0942401 0.09100642 0.0300951 -2,85 0.004 0.8529497 - 0.9710031
Urea 0.0105207 1.010576 0.0039576 2.69 0.007 1.002849 - 1.018363
Hemoglobin -0.2974991 0.7426733 0.0740307 -2.98 0.003 0.61087 - 0.9029148
Age -0.0132896 0.9867981 0.014454 -0.91 0.364 0.9588717 - 1.015538
Glycemia -0.0099115 0.9901375 0.0056338 -1.74 0.082 0.9791568 - 1.001241
EF (RI) - left ventricular ejection fraction by radionuclide; 95% CI – 95% confidence interval.
Table 1 - Variables selected for the multivariate analysis by the Cox Regression Model
Variable Hazard ratio Standard error Z p>| z | [95% CI]
Diastolic d. 0.9820524 0.0234101 -0.76 0.447 0.9372248-1.029024
EF (echo) 2.2516628 5.123265 0.36 0.721 0.0260439-194.6645
EF (RI) 0.9061327 0.0325586 -2.74 0.006 0.8445142-0.9722471
SAP 0.9873396 0.012824 -0.98 0.327 0.9625223-1.012797
Urea 1.008917 0.0048126 1.86 0.063 0.999528-1.018393
Sodium 0.9743023 0.0411025 -0.62 0.537 0.8969835-1.058286
Glycemia 0.9912635 0.007233 -1.2 0.229 0.9771879-1.005542
Hemoglobin 0.7860301 0.0833328 -2.27 0.023 0.6385533-0.9675675
Age 0.9913893 0.0164288 -0.52 0.602 0.9597067-1.024118
FC 1.466586 0.6007324 0.93 0.350 0.6571199-3.273185
Etiology 0.7617017 0.1532818 -1.35 0.176 0.5134433-1.129997
Sex 0.8414009 0.4206375 -0.35 0.730 0.3158391-2.241507
EF - ejection fraction; EF (RI) - left ventricular ejection fraction by radionuclide; SAP - systolic arterial pressure; FC - functional class; 95% CI – 95% confidence 
interval.
risk calculated for each patient varied from 0.0000424 to 
0.0019156. The score cutoff was established at 0.0011851, 
(Graphic 2), with a sensitivity of 82.86% and a specificity 
of 67.61%. The one-year and two-year event-free survival 
for low and high-risk patients were 92% and 76.06% and 
82.68% and 70.88% respectively (log rank p=0.00001) 
(Graphic 3).
Discussion
There are several studies in the literature regarding 
prognostic factors and risk scores for patients with HF followed 
at an outpatient clinic. However, there is a heterogeneity 
concerning these data. We analyzed the clinical and laboratory 
data of a sample of patients referred for heart transplantation, 
allowing us to select prognostic variables and, based on these 
variables, establish a prognostic score. 
Many studies suggest that the etiology of HF is an 
important prognostic factor9,10, despite being conflicting; 
there is a general trend that the ischemic etiology has a 
worse prognosis when compared to the non-ischemic 
etiology, which was not observed in the present study. 
Studies carried out in our country indicate that the Chagasic 
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etiology is an independent factor of worse prognosis11,12. At 
the survival rate analysis, we observed that Chagasic patients 
presented a worse evolution when compared to patients 
with ischemic etiology. The Chagasic etiology showed to be 
an independent prognostic factor at the univariate analysis, 
which was not maintained at the multivariate analysis. 
Additionally, we did not observe a higher incidence of 
sudden death in this group. 
Whenever the severity of HF symptoms is evaluated using 
the NYHA functional class classification, the functional classes 
III and IV seem to have the worse prognosis13-15. In our sample, 
Graphic 2 - ROC Curve for the level of the individual relative risk cutoff. Area under the curve = 0.7952.
Graphic 3 - Survival curve by the Kaplan-Meier method, for the individual relative risk, according to the ROC curve cutoff point, defined in Chart 2.
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the univariate analysis showed that functional classes III and IV 
were factors of worse prognosis, with no difference observed 
between them. However, at the multivariate analysis, the 
functional classes III and IV did not remain as indicators of 
worse prognosis. 
In our sample, the laboratory variables plasma bilirubin, 
albumin, glycemia, hemoglobin, urea and sodium were factors 
of worse prognosis at the univariate analysis. However, at 
the multivariate analysis, only plasma urea and hemoglobin 
remained as important prognostic factors. The serum sodium 
level have a strong inverse correlation with plasma renin activity 
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and is considered an important factor of worse prognosis in 
HF10,15-20. Our sample presented a median sodium level of 137 
± 4.96, which probably reflected the optimized treatment 
with ACEI and was not significant as a prognostic factor, even 
when the subgroups with sodium levels > or < 130mEq/l were 
analyzed. The increase in plasma urea and creatinine seems 
to be the worst prognosis factor in HF15,19-23.
The studies that assessed the influence of renal failure as 
a prognostic factor in HF indicated the importance of serum 
creatinine levels15, plasma urea and the estimated creatinine 
clearance22,23. In the present study, serum creatinine was not 
significant as a prognostic factor; however, plasma urea showed 
to be a strong predictor of mortality in both multi- and univariate 
analyses, which has been corroborated by other autors15.
Recent studies investigated a correlation between anemia 
and HF severity and showed that there was an improvement 
in the ejection fraction (EF), functional class and exercise 
capacity when anemia improved24-26. 
According to Horwich et al27, there is a correlation between 
low hemoglobin and the symptoms, exercise capacity and 
prognosis in patients with advanced HF; therefore, moderate 
anemia is not associated with increased morbidity and 
mortality in patients of both sexes. However, Sales et al28, 
evaluating hemoglobin and hematocrit levels in hospitalized 
elderly individuals, observed that male individuals with 
anemia presented higher mortality in comparison with female 
individuals and that anemia was an independent marker of 
in-hospital mortality.
In our sample, we did not consider the cases in which 
anemia was associated to the chronic disease and observed 
that male patients presented higher mortality when 
hemoglobin levels were < 14g/dl; such association was not 
observed in female patients when hemoglobin levels were < 
12g/dl. In the general analysis, after adjusting the variables, 
hemoglobin levels remained as an important prognostic factor 
in our sample. This information is in agreement with literature 
data and increases the interest on the role of erythropoietin 
in HF treatment.
The left ventricular ejection fraction obtained through 
radionuclide ventriculography10,13,17 has been increasingly 
appreciated as a strong prognostic indicator29. This variable 
showed to be discriminant as a high risk of death predictor at 
the multivariate analysis.
In our sample, the survival rate of patients referred for 
heart transplantation was 84.5% in the first year, 74.3% in 
the second year, 68.9% in the third year and 60.5% in the 
fifth year. When survival was assessed between the sexes, 
male sex survival in the first year was 85.7%, and the female 
was 81%; in the second year, it was 76.9% for males and 
67.5% for females and in five years, it was 62.4% for males 
and 64.8% for females. These survival rates are identical 
to those reported after heart transplantation published by 
“The Registry of the International Society for Heart and Lung 
Transplantation”30.
In comparison to literature data, the survival rate of patients 
in our sample was better, although they were critical patients 
referred for heart transplantation. When patients submitted to 
heart transplantation were excluded, the first-year survival was 
75.8% and the 2-year was 61%; considering only patients that 
were referred for heart transplantation, the first-year survival 
was 62.5% and the 2-year survival was 49.6%. These numbers 
suggest that the decision and the criteria used for patients’ 
transplantation referral were correct.
The assessment of the best moment for heart transplantation 
referral in outpatients remains difficult, as the criterion selection 
is not universally accepted and therefore, the establishment of 
a score has been used to try to help in this decision-making. 
The use of variables that are usually part of the clinical and 
laboratory assessments makes it more feasible to use the score 
routinely, although variables that are obtained invasively are 
equally important. 
Among the previously developed scores, some authors 
used variables that are not obtained by invasive methods, 
such as the score developed by Maeda et al21, who used 
HR, hemoglobin, serum potassium, serum total protein, 
albumin/globulin ratio, plasma urea, degree of hepatomegaly 
and the number of episodes of cardiac decompensation. The 
score by Aaronson et al10 considered the following variables: 
ischemic etiology, HR at rest, radionuclide EF, maximum 
oxygen consumption, intraventricular conduction delay and 
serum sodium. The score by Alla et al31 used: HR, serum 
creatinine, serum sodium, cardiac decompensation and 
age > 70 years. Among the studies that used data obtained 
from invasive methods in their scores are: Campana et al14, 
who used pulmonary diastolic arterial pressure minus the 
pulmonary capillary pressure, mean blood pressure, cardiac 
output, valvular heart disease, presence of B3 and functional 
class IV, whereas Martí et al32 used the mean pressure of the 
right atrium, the cardiac index and functional class IV. Of the 
aforementioned scores, only the one by Aaronson et al10 has 
a reasonable clinical acceptance, being the only one that has 
been validated prospectively. 
The non-conformity of the described scores is also an 
indication of the difficulties in considering the isolated weight 
of each prognostic factor in the evolution of heart failure. 
In our sample, the worse prognosis factors were the 
low ejection fraction at the radionuclide ventriculography, 
increase of plasma urea and low hemoglobin levels; based 
on these variables, we sought to establish a prognostic score 
that could objectively help determine the best moment for 
heart transplantation referral. This score showed to have 
reasonable sensitivity and specificity in the identification 
of patients at high risk of death. We believe the present 
study has created perspectives for carrying out a broader, 
prospective study that can validate an easy-to-apply score 
with a potential clinical usefulness. 
Study limitations - The fact that this is a retrospective study 
initiated in January 1986, a time when IECA, spironolactone 
and betablockers were still not established as first-choice 
therapy in the treatment of HF might somehow have interfered 
with the prognostic markers. Other study limitations were 
the non-systematic use of the direct measurement of O
2
 
consumption and the measurement of neurohormones (brain 
natriuretic peptide – BNP and plasma norepinephrine) and 
pro-inflammatory activity, which are seen as independent 
predictors of death. 
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A prospective study with a larger sample size is necessary 
to validate the prognostic factors and the risk score presented 
here.
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